RGEN Repligen Corporation

96.65
-4.06  -4%
Previous Close 100.71
Open 102.25
Price To Book 4.75
Market Cap 5,033,876,364
Shares 52,083,563
Volume 442,350
Short Ratio
Av. Daily Volume 596,226
Stock charts supplied by TradingView

NewsSee all news

  1. Repligen Appoints Rohin Mhatre, Ph.D. to Board of Directors

    WALTHAM, Mass., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment of life sciences industry executive Rohin Mhatre, Ph.D., to its Board of Directors. Dr. Mhatre brings

  2. Repligen Reports Fourth Quarter and Full Year 2019 Financial Results

    Reports quarterly revenue of $69.5 million, representing 34% year-over-year growth, and annual revenue of $270.2 million represents 39% year-over-year growthOverall organic revenue growth was 21% for the fourth quarter

  3. Repligen to Report Fourth Quarter and Full Year 2019 Financial Results

    WALTHAM, Mass., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter and full year 2019 financial results on Thursday, February 20, 2020.

  4. Repligen to Present at the 38th Annual J.P. Morgan Healthcare Conference

    WALTHAM, Mass., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that the Company will present at the 38th

  5. Repligen Reports Third Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance

    Reports quarterly revenue of $69.4 million, representing 40% reported growth and 28% organic growth year-over-yearRaises revenue guidance to $267-$270 million for full year 2019, representing 31%-32% organic growth

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

CRL received June 22, 2012.
RG1068
Detection of pancreatic duct abnormalities

Latest News

  1. Repligen Appoints Rohin Mhatre, Ph.D. to Board of Directors

    WALTHAM, Mass., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment of life sciences industry executive Rohin Mhatre, Ph.D., to its Board of Directors. Dr. Mhatre brings

  2. Repligen Reports Fourth Quarter and Full Year 2019 Financial Results

    Reports quarterly revenue of $69.5 million, representing 34% year-over-year growth, and annual revenue of $270.2 million represents 39% year-over-year growthOverall organic revenue growth was 21% for the fourth quarter

  3. Repligen to Report Fourth Quarter and Full Year 2019 Financial Results

    WALTHAM, Mass., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter and full year 2019 financial results on Thursday, February 20, 2020.

  4. Repligen to Present at the 38th Annual J.P. Morgan Healthcare Conference

    WALTHAM, Mass., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that the Company will present at the 38th

  5. Repligen Reports Third Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance

    Reports quarterly revenue of $69.4 million, representing 40% reported growth and 28% organic growth year-over-yearRaises revenue guidance to $267-$270 million for full year 2019, representing 31%-32% organic growth

  6. Repligen to Report Third Quarter 2019 Financial Results

    WALTHAM, Mass., Oct. 23, 2019 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2019 financial results on Thursday, October 31, 2019. The Company will

  7. Medicenna Strengthens Board of Directors by Appointment of Seasoned Biopharma Executive Ms. Karen Dawes

    Announces Results of Annual Meeting of Shareholders TORONTO and HOUSTON, Sept. 24, 2019 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX:MDNA, OTCQB:MDNAF), a clinical stage

  8. Medicenna Strengthens Board of Directors by Appointment of Seasoned Biopharma Executive Ms. Karen Dawes

    Announces Results of Annual Meeting of Shareholders TORONTO and HOUSTON, Sept. 24, 2019 /PRNewswire/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX:MDNA, OTCQB:MDNAF), a clinical